1 Dynamics of T cell responses to COVID-19 vaccines and breakthrough infection in 2 people living with HIV receiving antiretroviral therapy 3 4 5 Sneha Datwani^{1*}, Rebecca Kalikawe^{1*}, Rachel Waterworth^{1,3}, Francis M. Mwimanzi¹, Richard Liang², Yurou Sang¹, Hope R. Lapointe², Peter K. Cheung^{1,2}, F. Harrison 6 Omondi^{1,2}, Maggie C. Duncan^{1,2}, Evan Barad^{1,2}, Sarah Speckmaier², Nadia Moran-7 Garcia², Mari L. DeMarco^{4,5}, Malcolm Hedgcock⁶, Cecilia T. Costiniuk⁷, Mark Hull^{2,8}, 8 Marianne Harris^{2,9}, Marc G. Romney^{4,5}, Julio S.G. Montaner^{2,8}, Zabrina L. Brumme^{1,2}#, 9 10 Mark A. Brockman^{1,2,3}# 11 12 ¹ Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada; 13 ² British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada 14 ³ Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, 15 Canada; 16 ⁴ Department of Pathology and Laboratory Medicine, Providence Health Care, 17 Vancouver, Canada; ⁵ Department of Pathology and Laboratory Medicine, University of British Columbia, 18 19 Vancouver, Canada 20 ⁶ Spectrum Health, Vancouver, Canada 21 ⁷ Division of Infectious Diseases and Chronic Viral Illness Service, McGill University 22 Health Centre and Research Institute of the McGill University Health Centre, Montreal, 23 Ouebec, Canada 24 ⁸Department of Medicine, University of British Columbia, Vancouver, Canada; 25 ⁹Department of Family Practice, Faculty of Medicine, University of British Columbia, 26 Canada 27 28 *equal contribution 29 #Corresponding authors: MAB, mark brockman@sfu.ca; ZLB, zbrumme@sfu.ca 30 31 Abstract: 349 words 32 Text: 4,102 words 33 Inserts: 5 (1 Table, 4 Figures) 34 Supplemental files: 5 (2 Supplemental Figures, 3 Supplemental Tables) 35 36 Keywords: Covid-19, SARS-CoV-2, coronavirus, vaccine, T cells, HIV, antiretroviral 37 therapy 38

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

ABSTRACT (349 words) **Introduction:** People living with HIV (PLWH) can exhibit impaired immune responses to vaccines. Accumulating evidence indicates that PLWH, particularly those receiving antiretroviral therapy, mount strong antibody responses to COVID-19 vaccination, but fewer studies have examined cellular immune responses to vaccination. We measured SARS-CoV-2 spike-specific CD4+ and CD8+ T cell responses generated by two and three doses of COVID-19 vaccine in PLWH receiving antiretroviral therapy, compared to control participants without HIV. We also quantified T cell responses after post-vaccine breakthrough infection, and receipt of fourth vaccine doses, in a subset of PLWH. **Methods:** We quantified CD4+ and CD8+ T cells reactive to overlapping peptides spanning the ancestral SARS-CoV-2 spike protein in 50 PLWH and 87 controls without HIV, using an activation induced marker (AIM) assay. All participants remained SARS-CoV-2 naïve until at least one month after their third vaccine dose. SARS-CoV-2 infection was determined by seroconversion to nucleocapsid (N) antigen, which occurred in 21 PLWH and 38 controls post-third dose. Multivariable regression analyses were used to investigate relationships between sociodemographic, health and vaccine-related variables and vaccine-induced T cell responses, as well as breakthrough infection risk. **Results:** A third vaccine dose boosted spike-specific CD4+ and CD8+ T cell frequencies significantly above those measured after the second dose (all p<0.0001). Median T cell frequencies did not differ between PLWH and controls after the second dose (p>0.1), but CD8+ T cell responses were modestly lower in PLWH after the third dose (p=0.02), an

observation that remained significant after adjustment for sociodemographic, health and vaccine-related variables (p=0.045). In PLWH who experienced breakthrough infection, median T cell frequencies increased even higher than those observed after three vaccine doses (p<0.03), and CD8+ T cell responses in this group remained higher even after a fourth vaccine dose (p=0.03). In multivariable analysis, the only factor associated with increased breakthrough infection risk was younger age, consistent with the rapid increases in SARS-CoV-2 seropositivity among younger adults in Canada after the initial appearance of the Omicron variant.

Conclusion: PLWH receiving antiretroviral therapy mount strong T cell responses to COVID-19 vaccines that can be enhanced by booster doses or breakthrough infection.

INTRODUCTION

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

Prior to the widespread availability of COVID-19 vaccines, there was evidence that people living with HIV (PLWH) were at increased risk of severe COVID-19 outcomes [1-5], making vaccination particularly important in this group. Since then, a growing body of evidence indicates that COVID-19 vaccines have been highly effective at preventing severe disease associated with SARS-CoV-2 infection, including in PLWH [6, 7]. Studies analyzing vaccine-induced immune responses, including from our group, also confirm that PLWH, in particular those who are receiving suppressive antiretroviral therapy, mount robust humoral (antibody) response to COVID-19 immunization [8-16]. But comparably fewer studies have investigated the cellular immune response to COVID-19 vaccines in PLWH, which includes CD4+ helper T cells that play a central role in generating antigen-specific B cells and antibodies and CD8+ cytotoxic T cells that recognize and eliminate virus-infected cells [17-20]. Indeed, while COVID-19 vaccines typically induce strong T cell responses [21, 22], the frequency of spike-specific CD4+ T cells following COVID-19 vaccination may be lower in PLWH, in particularly among those with low CD4+ T cell counts [9, 23]. A better understanding of T cell responses elicited by COVID-19 vaccines, as well as breakthrough SARS-CoV-2 infections, will inform ongoing efforts to enhance protective immunity in PLWH. Towards this goal, we investigated the dynamics of spike-specific CD4+ and CD8+ T cell responses elicited after two and three doses of COVID-19 vaccine in a cohort of 50 adult PLWH receiving antiretroviral therapy, and 87 controls without HIV. All participants remained naïve to SARS-CoV-2 until at least one month after their third dose. We additionally investigated spike-specific CD4+ and CD8+ T cell responses in a

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

subset of 21 PLWH who experienced their first SARS-CoV-2 breakthrough infection between one and six months after their third vaccine dose. Overall, our results revealed that spike-specific CD4+ and CD8+ T cell frequencies were boosted with each vaccine dose, and that these responses were broadly comparable between PLWH and controls, with the exception of CD8+ T cell responses after the third dose, which were moderately lower in PLWH compared to controls. Breakthrough infection further boosted median spike-specific T cell frequencies, and CD8+ T cell responses remained higher in these individuals even after a fourth vaccine dose. **METHODS** Participants. Our cohort of COVID-19 vaccine recipients, based in British Columbia (BC) Canada, has been described previously [10, 13, 24]. Of the 99 PLWH and 152 controls (without HIV) originally enrolled in the study, 62 (PLWH) and 117 (controls) remained naïve for SARS-CoV-2 infection until at least one month after their third COVID-19 vaccine dose. Of these, we examined a subset of 50 PLWH and 87 controls, selected largely based on sample availability (**Table 1**). Ethics approval. Written informed consent was obtained from all participants. This study was approved by the University of British Columbia/Providence Health Care and Simon Fraser University Research Ethics Boards. SARS-CoV-2 seroconversion. SARS-CoV-2 infection was identified based on the development of serum antibodies against the viral Nucleocapsid (N) protein using the

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

Elecsys Anti-SARS-CoV-2 assay (Roche Diagnostics), combined with diagnostic (PCRand/or rapid-antigen-test) information where available. T cell activation induced marker assays. Cryopreserved peripheral blood mononuclear cells (PBMC) were thawed and diluted in TexMACS media (Miltenyi Biotec, Cat#130-097-196). PBMC were stimulated at 1 x 10⁶ cells per well for 24 hours with peptide pools spanning the SARS-CoV-2 ancestral spike protein (15-mers, overlapping by 11 amino acids) (Miltenyi Biotec, Cat#130-127-953) in duplicate in a 96-well U-bottom plate. PBMC were incubated with media only (no peptide) as a negative control or 2 µg/ml CytoStim reagent (Miltenyi Biotec, Cat#130-092-172) as a positive control. Following stimulation, cells were labeled with CD8-APC/Cyanine7 (Biolegend, Cat#301016), CD4-FITC (Biolegend, Cat#300538), CD137-APC (Biolegend, Cat#309810), CD69-PE (BD, Cat#555531), OX40-PE-Cy7 (Biolegend, Cat#350012), CD3-PerCP/Cyanine5.5 (Biolegend, Cat#317336) CD14-V500 (BD, Cat#561391), CD19-V500 (BD, Cat#561121) and 7-AAD Viability Staining Solution (Biolegend, Cat#420404). Data were acquired on a Beckman Coulter Cytoflex S flow cytometer, with a minimum of 10,000 CD3+ T cells assayed per participant. After identifying CD3+CD4+ and CD3+CD8+ T cell subsets, the percentage of stimulated cells was determined based on upregulation of two activation markers, using CD137 and OX40 for CD4+ T cells, and CD137 and CD69 for CD8+ T cells (see gating strategy in **Figure S1**). Data were analyzed in FlowJo version 10.8.1.

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

SARS-CoV-2 neutralization. We previously reported the ability of participant plasma to neutralize ancestral SARS-CoV-2 (isolate USA-WA1/2020; BEI Resources, Cat #NR-52281), based on the results of a live-virus assay [24]. Statistical analyses. Continuous variables were compared using the Mann-Whitney Utest (for unpaired data) or Wilcoxon test (for paired measures). Relationships between continuous variables were assessed using Spearman's correlation. Zero-inflated beta regressions were used to investigate the relationship between sociodemographic factors and vaccine-induced T cell responses using a confounder model that adjusted for variables that could influence these responses, or that differed in prevalence between groups. These regressions model the response variable as a beta-distributed random variable whose mean is given by a linear combination of the predictor variables (after a logit transformation). Beta distributions are bounded below and above by 0 and 100%, making this a standard choice of regression for frequency data. Because a beta distribution does not admit values of 0 (or 100), we used a zero-inflated beta distribution, which allows for zeros in the data, to accommodate the minority of non-responders (i.e. 0) values) in our data. For analyses performed after two-dose vaccination, included variables were: HIV status (non-PLWH as reference), age (per year), sex at birth (female as reference), ethnicity (non-white as reference), chronic conditions (per condition), ChAdOx1-containing initial vaccine regimen (mRNA only vaccination as reference) and the interval between first and second doses (per day). Analyses performed after threedose vaccination also included the third COVID-19 mRNA dose brand (BNT162b2 as reference), the interval between second and third doses (per day), and the % spikespecific T cells after two doses (per percent increase). Multivariable logistic regression was used to explore the relationship between these same variables and the risk of SARS-CoV-2 breakthrough infection between one and six months after the third vaccine dose. All tests were two-tailed, with p<0.05 considered statistically significant. Analyses were conducted using Prism v9.2.0 (GraphPad) and in R.

RESULTS

Participant characteristics

Characteristics of the 50 PLWH and 87 controls without HIV are shown in **Table 1**. All participants remained COVID-19 naïve until at least one month after their third vaccine dose, as confirmed by repeated negative serology for SARS-CoV-2 anti-N antibodies, and lack of reporting of any SARS-CoV-2 positive test result (either by PCR or rapid antigen test), up to this time point. PLWH and controls were a median age of 58 (interquartile range [IQR] 42-65) and 50 (IQR 35-72) years old, respectively, and predominantly of white ethnicity (72% of PLWH and 57% of controls). Most PLWH were male (88%, reflecting the overall population of PLWH in BC), while most controls were female (67%, broadly reflecting the overall demographics of health care workers in the region, from which the controls were predominantly recruited). Both groups reported few chronic health conditions (excluding HIV infection; median 1 [IQR 0-1] in PLWH, versus median 0 [IQR 0-1] in controls). All PLWH were receiving combination antiretroviral therapy, with a median HIV plasma viral load of <50 copies/mL (IQR <50 - <50 copies/mL) at study entry. The median CD4+ T cell count at study entry among

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

PLWH was 695 (IQR 468-983) cells per mm³, while median nadir CD4+ T cell count was 250 (IQR 140-490) cells per mm³. Most participants (84% of PLWH and 97% of controls) initially received two doses of mRNA vaccine, either BNT162b2 or mRNA-1273; the remainder received at least one ChAdOx1 dose in their initial series. In PLWH, second vaccine doses were administered a median of 59 days after the first, compared to an median interval of 89 days in controls (p<0.0001). This is because Canada delayed second doses well beyond the manufacturers' recommended 21-28 day interval, due to initially limited availability of vaccine supplies in the country [25]. As a result, individuals who received their first doses early in the vaccination campaign, including most health care workers, generally waited the longest to receive their second doses. Retrospectively, it was determined that delaying second doses did not reduce vaccine efficacy, and in some cases may have enhanced protection [26] and reduced the risk of myocarditis [27], prompting the World Health Organization to recommend a 2-month (~60-day) interval between first and second doses [28]. As a result, our multivariable analyses adjust for between-dose intervals and other sociodemographic and clinical attributes listed in Table 1. Third vaccine doses were predominantly mRNA-1273 (66% of PLWH and 61% of controls) and were administered a median of 182 to 197 days (approximately 6 to 6.5 months) after the second dose. Third mRNA-1273 dose amounts also differed by age and health history: according to vaccine guidelines in British Columbia, adults 65 years of age and older, as well as PLWH with a history of immunodeficiency, were eligible for a 100 mcg dose whereas all others were eligible for a 50 mcg booster dose (all BNT162b2 doses were 30 mcg). A total of 21 (42%) of PLWH and 38 (44%) of controls experienced their

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

first SARS-CoV-2 infection between one and six months after the third vaccine dose, as determined by seroconversion to the SARS-CoV-2 N protein and/or self-reported positive SARS-CoV-2 test results where available. Though viral genotyping was not performed for these "breakthrough" infections, these were likely Omicron BA.1 or BA.2 based on local molecular epidemiology trends at the time [29]. T cell responses following two and three COVID-19 vaccine doses Prior to vaccination, the percentage of spike-specific CD4+ and CD8+ T cells, measured in a subset of 10 PLWH and 15 controls, was negligible as expected (Figures 1A, 1B). Following two vaccine doses, the percentage of spike-specific CD4+ T cells increased significantly from pre-vaccine levels (paired measures p≤0.004 for both PLWH and controls), reaching a median 0.25% (IQR 0.07-0.50) in PLWH and a median 0.32% (IQR 0.15-0.55) in controls, a difference that was not statistically significant between groups (p=0.11; **Figure 1A**). CD8+ T cell responses also increased significantly from pre-vaccine levels following two vaccine doses (paired measures p≤0.002 in both groups), reaching a median 0.39% (IQR 0.22-0.53) in PLWH and a median 0.31% (IQR 0.14-0.61) in controls, a difference that was not statistically significant between groups (p=0.39; Figure 1B). The lack of statistically significant differences in vaccine-induced T cell responses between PLWH and controls remained after controlling for sociodemographic, health and vaccine-related variables (p=0.08 for CD4+ T cell responses; p=0.99 for CD8+ T cell responses; **Tables S1 and S2**). Of note, these multivariable analyses did not identify any variables that were significantly associated with spikespecific CD4+ T cell responses after two vaccine doses (Table S1), though having

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

received at least one ChAdOx1 dose as part of the initial vaccine series was weakly associated with higher spike-specific CD8+ T cell responses after the second vaccine dose (p=0.049; **Table S2**). A third vaccine dose further boosted the percentage of spike-specific CD4+ T cells beyond the levels observed after two doses (paired measures p<0.0001 for both PLWH and controls; Figure 1A). After the third dose, spike-specific CD4+ T cell frequencies reached a median 0.67% (IQR 0.50-0.86) in PLWH compared to a median 0.71% (IQR 0.40-0.98) in controls (p=0.52; **Figure 1A**), where this lack of significant difference between groups remained after controlling for sociodemographic, health and vaccine-related variables (p=0.58; **Table S1**). Similarly, a third vaccine dose further boosted the percentage of spike-specific CD8+ T cells (paired measures p<0.0001 for both groups; Figure 1B). Somewhat in contrast to the other immune measures however, the median CD8+ T cell response in PLWH (0.61%; IQR 0.43-0.79) was lower compared to that of controls $(0.78\%; IQR\ 0.43-1.1)$ after the third vaccine dose (p=0.02; **Figure** 1B). This difference remained marginally statistically significant after controlling for sociodemographic, health and vaccine-related variables (p=0.045; **Table S2**). The multivariable analyses also revealed that by far the strongest predictors of spike-specific CD4+ and CD8+ T cell responses after three vaccine doses were the corresponding percentage of spike-specific T cells achieved after two doses (Tables S1, **S2**). For example, the zero-inflated beta regression estimates for the impact of each 1% increment in post-second dose T cell frequencies on post-third dose frequencies were 0.71 for CD4+ T cells (p<2×10⁻¹⁶) and 0.79 for CD8+ T cells (p<2×10⁻¹⁶). To interpret these estimates: if the value of the linear predictor was x for a given set of values of the

predictors, and the % of spike-specific CD4+ T cells after two vaccine doses was increased by 1%, the resulting value of the linear predictor would now be x + 0.71, which translates to a non-linear increase in the regressed mean from 100*logit(x) to 100*logit(x + 0.71), where the factor of 100 converts the proportions to percentages. Male sex, receipt of an mRNA-1273 booster, and, somewhat unexpectedly, a higher number of chronic health conditions, were also independently associated with higher spike-specific CD4+ T cell responses (estimates 0.11 - 0.24; all p<0.04; **Table S1**). We hypothesize that the association between chronic health conditions and better T cell responses is because, after adjusting for post-second-dose responses, individuals with such conditions benefited particularly from a third dose. The association with mRNA-1273 is likely because adults aged 65 years and older, as well as PLWH with a history of immune dysfunction were eligible for the higher (100mcg) mRNA-1273 third dose in British Columbia, whereas the general population received the standard 50 mcg booster dose.

Correlations between vaccine-induced T cell responses and other immune measures

The percentages of spike-specific CD4+ and CD8+ T cells were strongly associated with one another after the second vaccine dose (Spearman's ρ =0.57; p<0.0001) as well as after the third dose (Spearman's ρ =0.54; p<0.0001; **Figure 2A**). No association was observed between the percentage of spike-specific CD4+ T cells and the magnitude of vaccine-induced neutralizing antibody responses based on a live-virus assay (reported previously by our group [24]) after either the second (Spearman's ρ =-0.04, p=0.7) or third dose (Spearman's ρ =-0.07, p=0.4; **Figure 2B**). Prior studies have linked the frequency of

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

CD4+ T follicular helper cells with antibody responses [30], but we did not assess T cell subsets here. As CD4+ T cell counts are used as an indicator of immune function in PLWH, we evaluated the relationship between this parameter and vaccine-induced T cell responses in this group. We observed no association between the most recent CD4+ T cell count and the frequency of either spike-specific CD4+ or CD8+ T cells following the second or third vaccine doses (Spearman's ρ =-0.09 to -0.18; all p>0.2; Figure S2). Similarly, we observed no association between nadir CD4+ T cell counts and vaccine-induced CD4+ T cell responses after either dose (Spearman's ρ =-0.05 and -0.12, respectively, both p>0.4) (Figure S2). By contrast, an unexpected modest negative correlation was found between nadir CD4+ T cell counts and spike-specific CD8+ T cell responses after both the second (Spearman's ρ =-0.29, p=0.04) and third (Spearman's ρ =-0.28, p=0.05) dose. We hypothesize that the post-third-dose results are because PLWH with a history of immune dysfunction were eligible for a higher (100 mcg) third dose of mRNA-1273, though this would not explain our post-second-dose results. Regardless, there is no indication that a low nadir CD4+ count impaired T cell responses to COVID-19 vaccination in our cohort. Breakthrough infection further boosts CD4+ and CD8+ T cell responses In British Columbia, the initial waves of Omicron BA.1 and BA.2 occurred after the mass administration of third vaccine doses in the province. Of the 50 PLWH studied, 21 (42%) PLWH experienced SARS-CoV-2 breakthrough infections between 1 and 6 months following their third dose. Post-breakthrough plasma and PBMC specimens were

available from nearly all PLWH, so we further examined humoral (neutralizing antibody)

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

and cellular immune responses 6 months after the third dose, and again one month after receipt of a fourth vaccine dose, in the PLWH cohort (n=50) (Figure 3). As we reported previously [12, 24], plasma neutralizing antibody activity declined significantly among SARS-CoV-2-naïve individuals after the third vaccine dose, but in those who experienced breakthrough infection, neutralization activity increased to above peak levels induced by vaccination. For example, at 6 months post-third vaccine dose, the median virus neutralization titer (reported as a reciprocal dilution) was 640 (IQR 320-2560) in PLWH who experienced a breakthrough infection, double the observed value in this group after three vaccine doses alone (paired test, p=0.002; Figure 3A). This neutralization titer was also eight times higher than the median titer of 80 (IQR 20-160) observed at 6 months post-third vaccine dose in PLWH who remained SARS-CoV-2 naïve (p<0.0001; **Figure 3A**). The observation that neutralization titers increase significantly following breakthrough infection confirms the ongoing presence of spikespecific memory B cells despite diminished neutralizing activity in blood. In contrast to neutralizing antibodies, spike-specific CD4+ and CD8+ T cell frequencies did not wane in SARS-CoV-2 naïve PLWH following vaccination. In fact, the percentage of both spike-specific CD4+ and CD8+ T cells increased slightly between 1 and 6 months after the third vaccine dose (paired p=0.003 and p=0.005 respectively, Figures 3B and 3C), consistent with the continued presence of vaccine-induced T cells even in the absence of antigen. Like humoral responses however, breakthrough infection boosted T cell responses to levels higher than those observed in the same participants after vaccination alone (both paired tests $p \le 0.0001$; Figures 3B and 3C). Moreover, the median percentage of spike-specific CD4+ T cells at 6 months post-third vaccine dose in

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

breakthrough cases was a 1.01% (IQR 0.78-1.51), compared to 0.70% (IQR 0.60-1.02) in SARS-CoV-2- naïve participants at this same time point (p=0.03; Figure 3B), while the median percentage of spike-specific CD8+ T cells in breakthrough cases was 1.20% (IQR 0.96-1.55), compared to 0.80% (IQR 0.60-1.02) in SARS-CoV-2 naïve participants at this time point (p=0.002; Figure 3C). A fourth vaccine dose significantly increased neutralizing antibody responses and spike-specific T cell responses in SARS-CoV-2 naïve PLWH (all paired tests p≤0.0001; Figures 3A, 3B, 3C), illustrating the immune benefit of a fourth vaccine dose in the absence of SARS-CoV-2 infection. A fourth dose also significantly increased humoral and cellular immune responses in PLWH who experienced prior breakthrough infection (all paired tests p<0.03; Figures 3A, 3B, 3C). Of note, post-fourth dose neutralizing antibody titers and CD8+ T cell responses in PLWH who experienced breakthrough infection were significantly higher than among SARS-CoV-2 naïve PLWH at this same time (p=0.001 and p=0.03 respectively; **Figures 3A and 3C**), consistent with prior reports of superior "hybrid" immunity generated by a combination of vaccination and infection [31, 32]. Correlates of protection against breakthrough infection Given the substantial proportion of participants who experienced their first SARS-CoV-2 breakthrough infection between one and six months following three-dose vaccination (42% of PLWH; 44% of controls), we explored our data for potential correlates of protection. As HIV status was not associated with breakthrough infection (p=0.86), PLWH and control groups were combined for analysis, yielding 78 participants

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

who remained SARS-CoV-2 naïve and 59 participants who experienced SARS-CoV-2 infection during the follow-up period. Univariable analyses revealed older age to be significantly associated with protection against breakthrough infection: participants remaining SARS-CoV-2 naïve were a median 60 [IQR 42-71] years old while those who experienced breakthrough infection were a median 43 [IQR 34-60] years old (combined cohort p=0.001; Figure 4A). This observation was largely driven by the control group, which included 29 adults age 70 years or over (compared to 3 in the PLWH group). The percentage of spike-specific CD4+ T cells one month after the third vaccine dose was not associated with breakthrough infection (p=0.72 for the combined cohort; Figure 4B), but a higher percentage of spike-specific CD8+ T cells at this time point was associated with remaining SARS-CoV-2 naïve (p=0.046 for the combined cohort) (Figure 4C). This observation was driven by differences in CD8+ T cell responses among PLWH (p=0.02) and suggests that cytotoxic T cells specific for SARS-CoV-2 may contribute to protection. Somewhat surprisingly, we found no association between neutralizing antibody responses induced by three vaccine doses and breakthrough infections (p=0.33) for the combined cohort) (Figure 4D), likely because vaccine-induced antibodies against the ancestral (Wuhan) spike had limited activity against the Omicron strains that caused the majority of breakthrough infections, and because these infections occurred a median of 3.7 months after booster vaccination, when circulating antibody titers had declined substantially. In a multivariable logistic regression analysis that incorporated participant sociodemographic, vaccine and immune response variables, older age was the only significant predictor of protection against SARS-CoV-2 breakthrough infection (Table **S3**). Though at first surprising, this observation is consistent with the very rapid rise in

SARS-CoV-2 anti-N seroprevalence in Canada among younger individuals following the emergence of Omicron, and likely reflects the impact of social/behavioural factors rather than biological factors. For example, by mid-June 2022, anti-N seroprevalence in Canadian adults aged < 25 years was 57%, in those aged 25–39 years it was 51%, in those aged 40–59 years it was 40%, and in those 60 years or older it was 25% [33]. Similar age-specific trends were observed in Finland [34] and the USA [35], suggesting that many older adults continued to benefit from efforts to limit exposure to COVID-19 in the community, even after the arrival of Omicron.

DISCUSSION

We observed that the frequencies of SARS-CoV-2 spike-specific CD4+ and CD8+ T cells were not significantly different between PLWH and controls after two doses of COVID-19 vaccine. Both CD4+ and CD8+ T cell responses were enhanced following a third vaccine dose, but the frequency of spike-specific CD8+ T cells was modestly lower in PLWH compared to controls. PLWH generated robust spike-specific T cell responses following post-vaccine breakthrough infection, reaching levels that were equivalent to those achieved after a fourth vaccine dose in SARS-CoV-2 naïve PLWH. Of note, receiving a fourth vaccine dose after having experienced a breakthrough SARS-CoV-2 infection enhanced immune responses even further, with neutralizing antibody responses and CD8+ T cell responses reaching levels significantly higher than those observed in SARS-CoV-2 naïve individuals after four doses. This finding is consistent with previous reports describing the superiority of "hybrid" immunity generated through a combination of vaccination and infection [31, 32].

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

Our results are broadly consistent with other recent studies showing that vaccineinduced spike-specific T cell responses are equivalent in PLWH and controls without HIV, particularly among PLWH receiving antiretroviral therapy [9, 17-20, 23]. We found no association between CD4+ T cell responses and neutralizing antibodies after either two or three vaccine doses, suggesting that sufficient T cell help was provided to stimulate spike-specific B cell responses despite a wide range of antigen-specific CD4+ T cell frequencies induced by vaccination. While our results do not rule out potential dysfunction in vaccine-induced T cells among PLWH, our data suggest that the impact of T cell impairment is likely to be modest after the second and third vaccine dose. This study has some limitations. All PLWH were receiving suppressive antiretroviral therapy and had generally preserved CD4+ T cell counts, so our observations may not be generalizable to PLWH who have low CD4+ T cell counts or untreated HIV. Since this was an observational study, PLWH and control participants were not matched at enrolment. Though we included known variables in multivariable regression analyses, residual effects of variables that differed between groups (e.g. sex, vaccine regimen type) or other unknown factors could influence our results. We also lacked information on the concentration of mRNA-1273 third doses (100 mcg versus 50 mcg), and therefore we could not investigate the impact of this on immune responses. While the activation induced marker assay provides a sensitive method to quantify spikespecific CD4+ and CD8+ T cells, we did not analyze T cell subsets such as follicular helper cells, nor T cell functions such as cytokine production or proliferation, that could reveal differences in the effector activity of vaccine- or infection-induced responses. Finally, since T cell responses were measured using peptide pools spanning only the

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

ancestral spike protein, we cannot comment on the relative dominance of individual T cell epitopes nor on potential changes in the distribution of T cell responses following repeated vaccination or breakthrough infection. CONCLUSIONS In summary, our study indicates that PLWH who are receiving suppressive antiretroviral therapy mount strong CD4+ and CD8+ T cell responses to COVID-19 vaccines that are comparable to those found in individuals without HIV. Repeated exposure to SARS-CoV-2 spike antigen, either through vaccination or infection, further enhanced T cell responses in PLWH. PLWH status was not associated with increased risk of post-vaccine breakthrough infection in our cohort, but older age was found to be a significant predictor of protection against infection, consistent with lower SARS-CoV-2 anti-N seropositivity rates among older adults in Canada following the emergence of Omicron [33]. These results further underscore the benefits of COVID-19 vaccination in PLWH. **DECLARATIONS** Ethics approval and consent to participate Written informed consent was obtained from all participants. This study was approved by the University of British Columbia/Providence Health Care and Simon Fraser University Research Ethics Boards. **Consent for publication**

438 Not applicable. 439 440 Availability of data and materials 441 The datasets analysed in this study are available from the corresponding author 442 upon reasonable request. Data have also been deposited into the COVID-19 Immunology 443 Task Force (CITF) data bank (https://portal.citf.mcgill.ca/). 444 445 **Competing interests** 446 The authors declare that they have no competing interests. 447 448 **Funding** 449 This work was supported by the Public Health Agency of Canada through a 450 COVID-19 Immunology Task Force COVID-19 "Hot Spots" Award (2020-HQ-000120) 451 to MGR, ZLB, MAB). Additional funding was received from the Canadian Institutes for 452 Health Research (GA2-177713 to MAB), the Coronavirus Variants Rapid Response 453 Network (FRN-175622 to MAB), the Canada Foundation for Innovation through 454 Exceptional Opportunities Fund – COVID-19 awards (to MAB, MLD, ZLB). FMM was 455 supported by fellowships from the Canadian Institutes of Health Research (CIHR) 456 Canadian HIV Trials Network and Michael Smith Health Research BC (MSHR-BC). 457 FHO was supported by a Ph.D. fellowship from the Sub-Saharan African Network for 458 TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative (grant # DEL-15-459 006). The DELTAS Africa Initiative is an independent funding scheme of the African 460 Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

(AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant # 107752/Z/15/Z] and the UK government. MCD was supported by a CIHR CGS-M award. MLD and ZLB hold Scholar Awards from MSHR-BC. **Authors' contributions** SD, ZLB and MAB led the study. YS and HRL coordinated the study. SD and RK quantified T cell responses by flow cytometry. SD, RK, RW, FM, YS, SS, NM-G, MCD, FHO and EB processed specimens and collected data. PKC performed viral neutralization assays. SD, RK, MAB and ZLB analyzed data. RL performed statistical analyses. MLD and MGR supervised SARS-CoV-2 serum antibody quantification. MH, CTC, MH, MH, MGR and JGSM contributed to cohort establishment. ZLB and MAB drafted the manuscript. All authors contributed to manuscript review and editing. Acknowledgements We thank the leadership and staff of Providence Health Care, St. Paul's Hospital, the BC Centre for Excellence in HIV/AIDS, the Hope to Health Research and Innovation Centre, and Simon Fraser University for supporting this project. In particular, we thank Landon Young and Bruce Ganase for phlebotomy assistance; Laura Burns for technical assistance; Dr Junine Toy, Dr. Chanson Brumme and Paul Sereda for database assistance; and Drs. Silvia Guillemi, Rolando Barrios, Victor Leung, Janet Simons, Daniel Holmes, Curtis Cooper and Aslam Anis for clinical support and guidance. Finally, we thank the participants, without whom this study would not have been possible.

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

FIGURE LEGENDS Figure 1. SARS-CoV-2 spike-specific T cell responses after COVID-19 vaccination. Panel A: Spike-specific CD4+ T cell frequencies before and after two and three-dose COVID-19 vaccination. People living with HIV (PLWH) are in orange; controls without HIV (CTRL) are in blue. All participants are COVID-19 naïve. Red bars indicate median and IQR. The Mann-Whitney U-test was used for between-group comparisons and the Wilcoxon matched pairs test was used for longitudinal paired comparisons. P-values are not corrected for multiple comparisons. Panel B: Same as panel A, but for spike-specific CD8+ T cell frequencies. Figure 2. Associations between cellular and humoral immune measures after **COVID-19 vaccination.** Panel A: Correlation between spike-specific CD4+ and CD8+ T cell frequencies one month after the second dose (open circles) and one month after the third dose (closed circles) in people living with HIV (PLWH, in orange) and controls without HIV (in blue). Panel B: Correlation between spike-specific CD4+ T cell frequencies and SARS-CoV-2 neutralizing antibodies, measured at one month after the second dose (open circles) and one month after the third dose (closed circles) in people living with HIV (PLWH, in orange) and controls without HIV (in blue). All participants are COVID-19 naïve. Figure 3. Longitudinal SARS-CoV-2 spike-specific immune responses in PLWH who remained naïve or who experienced their first SARS-CoV-2 infection after **COVID-19 vaccination.** Panel A: SARS-CoV-2 neutralizing antibody titers (reciprocal

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

dilution) in people living with HIV (PLWH) after two, three and four doses of COVID-19 vaccine. Data from the same individual are connected by grey lines. SARS-CoV-2naïve participants are displayed in orange. SARS-CoV-2 breakthrough participants after the third dose are displayed in green (starting at the point of seroconversion). Note that many antibody titer values overlap, resulting in darker colored symbols. Asterisks denote naive participants who experienced SARS-CoV-2 breakthrough between six months postdose three and one month post-dose four. Red bars indicate median. The Mann-Whitney U-test was used for between-group comparisons and the Wilcoxon matched pairs test was used for longitudinal paired comparisons. P-values are not corrected for multiple comparisons. Panel B: Same as panel A, but for spike-specific CD4+ T cell responses. Panel C: Same as panels A and B, but for spike-specific CD8+ T cell responses. The Mann-Whitney U-test was used for between-group comparisons and the Wilcoxon matched pairs test was used for longitudinal paired comparisons. P-values are not corrected for multiple comparisons. Figure 4. Analysis of correlates of protection against SARS-CoV-2 breakthrough **infection after COVID-19 vaccination.** Panel A: Participant ages are shown at study entry, stratified according to those who remained SARS-CoV-2 naive (n=78) and those who experienced SARS-CoV-2 breakthrough infection between one and six months after receiving a third vaccine dose (n=59). PLWH are in orange; controls are in blue. Panel B: Same as panel A, except the frequencies of spike-specific CD4+ T cells one month after three vaccine doses are shown. Panel C: Same as panel A and B, except the frequencies of CD8+ T cells one month after three vaccine doses are shown. Panel D: Same as other

panels, except SARS-CoV-2 neutralization activities (reported as reciprocal dilution titers) one month after three vaccine doses are shown. For all panels, the Mann-Whitney U-test was used to compare groups, using data from the full cohort (all; n=137), from controls only (n=87), or from PLWH only (n=50).

REFERENCES

- Boulle A, Davies MA, Hussey H, Ismail M, Morden E, Vundle Z, Zweigenthal V,
- Mahomed H, Paleker M, Pienaar D et al: Risk factors for COVID-19 death in a
- 538 population cohort study from the Western Cape Province, South Africa. Clin Infect
- 539 Dis 2020.

535

- 540 2. Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, Villa G,
- Docherty A, Harrison EM, Turtle L et al: Outcomes of COVID-19 related
- hospitalization among people with HIV in the ISARIC WHO Clinical
- Characterization Protocol (UK): a prospective observational study. Clin Infect Dis
- 544 2020.
- 3. Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, Eggo
- RM, Morton CE, Bacon SCJ, Inglesby P et al: HIV infection and COVID-19 death: a
- 547 population-based cohort analysis of UK primary care data and linked national
- death registrations within the OpenSAFELY platform. Lancet HIV 2021, 8(1):e24-
- 549 e32.
- 550 4. Tesoriero JM, Swain CE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, Gonzalez
- CJ, Udo T, Morne JE, Hart-Malloy R et al: COVID-19 Outcomes Among Persons
- Living With or Without Diagnosed HIV Infection in New York State. JAMA network
- 553 open 2021, 4(2):e2037069.
- 554 5. Spinelli MA, Jones BLH, Gandhi M: COVID-19 Outcomes and Risk Factors
- Among People Living with HIV. Curr HIV/AIDS Rep 2022, 19(5):425-432.
- 556 6. Chambers C, Samii H, Cooper CL, Costiniuk CT, Janjua NZ, Kroch AE, Arbess
- 557 G, Benoit AC, Buchan SA, Chung H et al: Coronavirus disease 2019 vaccine
- effectiveness among a population-based cohort of people living with HIV. AIDS
- 559 2022, **36**(15):F17-F26.
- Fowokan A, Samji H, Puyat JH, Janjua NZ, Wilton J, Wong J, Grennan T,
- 561 Chambers C, Kroch A, Costiniuk CT et al: Effectiveness of COVID-19 vaccines in
- people living with HIV in British Columbia and comparisons with a matched HIV-
- 563 negative cohort: a test-negative design. Int J Infect Dis 2023, 127:162-170.
- 8. Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, Padayachee SD,
- Dheda K, Barnabas SL, Bhorat QE et al: Safety and immunogenicity of the ChAdOx1
- nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without
- HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-
- **controlled, phase 1B/2A trial**. *Lancet HIV* 2021, **8**(9):e568-e580.
- 569 9. Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A, Lanini S,
- De Pascale L, Matusali G, Mariotti D et al: Humoral and Cellular Immune Response
- 571 Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome
- 572 Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency

- 573 Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte
- 574 **Count**. *Clin Infect Dis* 2022, **75**(1):e552-e563.
- 575 10. Brumme ZL, Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Duncan MC,
- Yaseen F, Agafitei O, Ennis S, Ng K et al: Humoral immune responses to COVID-19
- vaccination in people living with HIV receiving suppressive antiretroviral therapy.
- 578 NPJ Vaccines 2022, 7(1):28.
- 579 11. Jedicke N, Stankov MV, Cossmann A, Dopfer-Jablonka A, Knuth C, Ahrenstorf
- 580 G, Ramos GM, Behrens GMN: Humoral immune response following prime and boost
- 581 BNT162b2 vaccination in people living with HIV on antiretroviral therapy. HIV Med
- 582 2022, **23**(5):558-563.
- Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Speckmaier S, Barad
- E, Moran-Garcia N, Datwani S, Duncan MC et al: Antibody response durability
- 585 following three-dose COVID-19 vaccination in people with HIV receiving
- suppressive ART. AIDS 2022.
- Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Umviligihozo G,
- Kalikawe R, Speckmaier S, Moran-Garcia N, Datwani S et al: People with HIV
- receiving suppressive antiretroviral therapy show typical antibody durability after
- dual COVID-19 vaccination, and strong third dose responses. J Infect Dis 2022.
- 591 14. Nault L, Marchitto L, Goyette G, Tremblay-Sher D, Fortin C, Martel-Laferrière
- V, Trottier B, Richard J, Durand M, Kaufmann D et al: Covid-19 vaccine
- immunogenicity in people living with HIV-1. Vaccine 2022, 40(26):3633-3637.
- 594 15. Vergori A, Cozzi Lepri A, Cicalini S, Matusali G, Bordoni V, Lanini S, Meschi S,
- Iannazzo R, Mazzotta V, Colavita F et al: Immunogenicity to COVID-19 mRNA
- vaccine third dose in people living with HIV. *Nat Commun* 2022, **13**(1):4922.
- 597 16. Woldemeskel BA, Karaba AH, Garliss CC, Beck EJ, Wang KH, Laeyendecker O,
- 598 Cox AL, Blankson JN: The BNT162b2 mRNA Vaccine Elicits Robust Humoral and
- 599 Cellular Immune Responses in People Living With Human Immunodeficiency Virus
- 600 (HIV). Clin Infect Dis 2022, 74(7):1268-1270.
- 601 17. Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, Alagaratnam J, Aley PK,
- Ali M, Ansari MA et al: Safety and immunogenicity of the ChAdOx1 nCoV-19
- 603 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of
- a phase 2/3 clinical trial. *Lancet HIV* 2021, **8**(8):e474-e485.
- 605 18. Fidler S, Fox J, Tipoe T, Longet S, Tipton T, Abeywickrema M, Adele S,
- Alagaratnam J, Ali M, Aley PK et al: Booster vaccination against SARS-CoV-2
- induces potent immune responses in people with HIV. Clin Infect Dis 2022.
- Hensley KS, Jongkees MJ, Geers D, GeurtsvanKessel CH, Mueller YM, Dalm V,
- Papageorgiou G, Steggink H, Gorska A, Bogers S et al: Immunogenicity and
- reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the

- Netherlands: A nationwide prospective cohort study. *PLoS Med* 2022,
- 612 **19**(10):e1003979.
- 613 20. Hung CY, Hsiao SH, Huang CG, Chang CS, Chen GY, Huang YL, Dutta A,
- Huang CT: Relatively preserved functional immune capacity with standard COVID-
- 615 19 vaccine regimen in people living with HIV. Front Immunol 2023, 14:1204314.
- Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A,
- Pascal K, Quandt J, Maurus D et al: COVID-19 vaccine BNT162b1 elicits human
- antibody and T(H)1 T cell responses. *Nature* 2020, **586**(7830):594-599.
- Painter MM, Mathew D, Goel RR, Apostolidis SA, Pattekar A, Kuthuru O, Baxter
- AE, Herati RS, Oldridge DA, Gouma S et al: Rapid induction of antigen-specific
- 621 CD4(+) T cells is associated with coordinated humoral and cellular immunity to
- 622 **SARS-CoV-2 mRNA vaccination**. *Immunity* 2021, **54**(9):2133-2142 e2133.
- 623 23. Matsumoto Y, Murata M, Ohta A, Yamasaki S, Ikezaki H, Toyoda K, Shimono
- N: The humoral and cellular immune responses following booster vaccination with
- 625 SARS-CoV-2 mRNA in people living with human immunodeficiency virus. J Infect
- 626 *Chemother* 2023.
- 627 24. Cheung PK, Lapointe HR, Sang Y, Ennis S, Mwimanzi F, Speckmaier S, Barad
- E, Dong W, Liang R, Simons J et al: SARS-CoV-2 live virus neutralization after four
- 629 COVID-19 vaccine doses in PWH receiving ART. AIDS 2023, Accepted, In Press.
- 630 25. PHAoC: NACI rapid response: Extended dose intervals for COVID-19
- vaccines to optimize early vaccine rollout and population protection in Canada.
- 632 https://www.canada.ca/en/public-health/services/immunization/national-advisory-
- 633 committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-
- vaccines-early-rollout-population-protection.html; 2021.
- 635 26. Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M,
- Talbot D, Prystajecky N, Tyson JR, Gilca R et al: Two-Dose Severe Acute Respiratory
- 637 Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and
- 638 Extended Dosing Intervals: Test-Negative Design Studies From British Columbia
- 639 and Quebec, Canada. Clin Infect Dis 2022, 75(11):1980-1992.
- Buchan SA, Seo CY, Johnson C, Alley S, Kwong JC, Nasreen S, Calzavara A, Lu
- D, Harris TM, Yu K et al: Epidemiology of Myocarditis and Pericarditis Following
- 642 mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among
- Adolescents and Adults in Ontario, Canada. JAMA Netw Open 2022, 5(6):e2218505.
- 644 28. Organization WH: Interim recommendations for use of the Moderna mRNA-
- 645 **1273 vaccine against COVID-19**. In.; 2021.
- Weekly update on Variants of Concern [http://www.bccdc.ca/health-
- 647 info/diseases-conditions/covid-19/data]

- 648 30. Lv Z, Lv S, Li Q, Xia Y, Feng Z, Zhang H, Yang H, Wu Z, Zou N, Mo Q et al: A
- 649 third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity
- and T follicular helper cell responses in people living with HIV. Front Immunol 2023,
- **651 14**:1264160.
- Bertoletti A, Le Bert N, Tan AT: SARS-CoV-2-specific T cells in the changing
- 653 **landscape of the COVID-19 pandemic**. *Immunity* 2022, **55**(10):1764-1778.
- Lapuente D, Winkler TH, Tenbusch M: **B-cell and antibody responses to**
- 655 SARS-CoV-2: infection, vaccination, and hybrid immunity. Cell Mol Immunol 2024,
- **21**(2):144-158.
- 657 33. Murphy TJ, Swail H, Jain J, Anderson M, Awadalla P, Behl L, Brown PE,
- 658 Charlton CL, Colwill K, Drews SJ et al: The evolution of SARS-CoV-2 seroprevalence
- 659 in Canada: a time-series study, 2020-2023. CMAJ 2023, 195(31):E1030-E1037.
- Ahava MJ, Jarva H, Jaaskelainen AJ, Lappalainen M, Vapalahti O, Kurkela S:
- Rapid increase in SARS-CoV-2 seroprevalence during the emergence of Omicron
- variant, Finland. Eur J Clin Microbiol Infect Dis 2022.
- 663 35. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, Gundlapalli AV, Hall
- AJ, MacNeil A: Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies -
- United States, September 2021-February 2022. MMWR Morb Mortal Wkly Rep 2022,
- **71**(17):606-608.

Table 1: Participant characteristics

Characteristic	PLWH (n=50)	Controls (n=87)	
Sociodemographic and health variables ^a	(H 20)	(H 07)	
Age in years, median [IQR]	58 [42-65]	50 [35-72]	
Female sex at birth, n (%)	6 (12%)	58 (67%)	
Non-white ethnicity, n (%)	14 (28%)	37 (43%)	
Number of chronic health conditions, median [IQR] ^b	1 [0-1]	0 [0-1]	
HIV plasma viral load (RNA copies per mL)	<50 [<50-<50]	N.A.	
Recent CD4 cell count (per mm ³), median [IQR]	695 [468-983]	N.A.	
Nadir CD4 cell count (per mm³), median [IQR]	250 [140-490]	N.A.	
Vaccine details			
Initial regimen ^c			
mRNA only, n (%)	42 (84%)	84 (97%)	
ChAdOx1-containing, n (%)	8 (16%)	3 (3%)	
Third dose	, ,	` ,	
BNT162b2, n (%)	17 (34%)	34 (39%)	
mRNA-1273, n (%)	33 (66%)	53 (61%)	
Days between first and second doses, median [IQR]	59 [53-68]	89 [73-98]	
Days between second and third doses, median [IQR]	182 [141-191]	197 [169-215]	
Post-3rd vaccine dose SARS-CoV-2 infections, n (%) ^d	21 (42%)	38 (44%)	


^aSociodemographic, health, and vaccine data were collected by self-report and confirmed through medical records where available. CD4+ T cell counts and HIV plasma viral loads were obtained from medical records.


^bChronic conditions were defined as hypertension, diabetes, asthma, obesity, chronic diseases of lung, liver, kidney, heart or blood, cancer, and immunosuppression due to chronic conditions or medication.


^cInitial regimen refers to the first two doses. "mRNA only" refers to participants who received BNT162b2 and/or mRNA-1273 while "ChAdOx1-containing" refers to participants who received two ChAdOx1 doses, or one ChAdOx1 dose plus one mRNA dose.

^dSARS-CoV-2 infections that occurred between one and six months after the third vaccine dose.

Figure 1










TABLE S1. Multivariable zero-inflated beta regressions exploring the relationship between sociodemographic, health and vaccine-related variables on Spike-specific CD4+ T cell responses following two and three COVID-19 vaccine doses

Variable	Outcome measures					
	% Spike-responsive CD4+ T cells after two vaccine doses			% Spike-responsive CD4+ T cells after three vaccine doses		
	Estimate	Standard error	P value	Estimate	Standard error	P value
PLWH group	-0.29	0.17	0.08	-0.06	0.10	0.58
Age (per year)	0.001	0.004	0.83	-0.004	0.002	0.08
Male sex	0.13	0.14	0.38	0.24	0.084	0.0044
White ethnicity	-0.19	0.14	0.16	-0.045	0.076	0.55
Health conditions (per condition) ^a	-0.03	0.08	0.72	0.11	0.047	0.022
ChAdOx1-containing initial vaccine regimen ^b	0.37	0.21	0.09	0.14	0.12	0.27
Days between 1st and 2nd vaccine dose (per day)	0.005	0.003	0.12	0.002	0.002	0.30
mRNA-1273 as third vaccine dose ^c	N.A.	N.A.	N.A.	0.17	0.077	0.033
Days between 2nd and 3rd vaccine dose (per day)	N.A.	N.A.	N.A.	0.001	0.001	0.47
% Spike specific T cells after two doses (per 1% increment)	N.A.	N.A.	N.A.	0.71	0.058	$<2x10^{-16}$

^aContinuous variable, defined as: chronic blood disorder, cancer, hypertension, diabetes, asthma, obesity (body mass index ≥30), chronic

diseases of lung, liver, kidney or heart

Binary variable, defined as two doses of ChAdOx1, or a heterologous regimen consisting of one dose each of ChAdOx1 and an mRNA vaccine (mRNA-1273 or BNT162b2) (vs. a reference group defined as two doses of mRNA vaccine)

^cBinary variable, defined as a third dose of mRNA-1273 (vs. a reference group defined as a third dose of BNT162b2)

TABLE S2. Multivariable zero-inflated beta regressions exploring the relationship between sociodemographic, health and vaccine-related variables on Spike-specific CD8+ T cell responses following two and three COVID-19 vaccine doses

Variable	Outcome measures					
	% Spike-responsive CD8+ T cells after two vaccine doses			% Spike-responsive CD8+ T cells after three vaccine doses		
	Estimate	Standard error	P value	Estimate	Standard error	P value
PLWH group	-0.0002	0.16	0.99	-0.24	0.12	0.045
Age (per year)	-0.001	0.004	0.87	0.001	0.004	0.87
Male sex	0.18	0.14	0.20	0.11	0.10	0.24
White ethnicity	0.14	0.13	0.30	-0.01	0.08	0.90
Health conditions (per condition) ^a	-0.02	0.08	0.75	-0.05	0.06	0.37
ChAdOx1-containing initial vaccine regimen ^b	0.39	0.20	0.049	0.22	0.14	0.12
Days between 1st and 2nd vaccine dose (per day)	0.002	0.003	0.54	0.00	0.00	0.16
mRNA-1273 as third vaccine dose ^c	N.A.	N.A.	N.A.	0.02	0.11	0.86
Days between 2nd and 3rd vaccine dose (per day)	N.A.	N.A.	N.A.	-0.001	0.002	0.43
% Spike specific T cells after two doses (per 1% increment)	N.A.	N.A.	N.A.	0.79	0.07	<2e-16

[&]quot;Continuous variable, defined as: chronic blood disorder, cancer, hypertension, diabetes, asthma, obesity (body mass index ≥30), chronic diseases of lung, liver, kidney or heart

^oBinary variable, defined as two doses of ChAdOx1, or a heterologous regimen consisting of one dose each of ChAdOx1 and an mRNA vaccine (mRNA-1273 or BNT162b2) (vs. a reference group defined as two doses of mRNA vaccine)

^cBinary variable, defined as a third dose of mRNA-1273 (vs. a reference group defined as a third dose of BNT162b2)

TABLE S3. Multivariable logistic regression looking at factors associated with risk of first breakthrough infection between 1 and 6 months following receipt of the 3rd COVID-19 vaccine dose

Variables	Estimate	95% CI	P value
PLWH group	0.93	0.30 to 2.78	0.89
Age (per year)	0.96	0.93 to 0.98	0.002
Male sex	0.68	0.27 to 1.66	0.40
White ethnicity	1.55	0.69 to 3.60	0.29
Health conditions (per condition) ^a	1.22	0.72 to 2.09	0.46
ChAdOx1-containing initial vaccine regimen ^b	2.02	0.52 to 8.27	0.31
Days between 1st and 2nd vaccine dose (per day)	1.00	0.97 to 1.02	0.76
mRNA-1273 as third vaccine dose ^c	1.09	0.49 to 2.47	0.84
Days between 2nd and 3rd vaccine dose (per day)	1.00	0.99 to 1.01	0.96
% Spike specific CD4+ T cells after three doses (per 1% increment)	0.76	0.25 to 2.13	0.61
% Spike specific CD8+ T cells after two doses (per 1% increment)	0.86	0.36 to 2.01	0.73
Virus neutralizing activirty (per 1% increment)	1.00	0.99 to 1.00	0.26

^aContinuous variable, defined as: chronic blood disorder, cancer, hypertension, diabetes, asthma, obesity (body mass index ≥30), chronic diseases of lung, liver, kidney or heart

^oBinary variable, defined as two doses of ChAdOx1, or a heterologous regimen consisting of one dose each of ChAdOx1 and an mRNA vaccine (mRNA-1273 or BNT162b2) (vs. a reference group defined as two doses of mRNA vaccine)

^cBinary variable, defined as a third dose of mRNA-1273 (vs. a reference group defined as a third dose of BNT162b2)




Figure S1. Gating strategy used to quantify vaccine-induced spike-specific T cell responses by flow cytometry.




Figure S2. Correlations between vaccine-induced spike-specific T cell responses and recent or nadir CD4 cell count in PLWH.